Beijing – August 7 2015 – MetaCure announced today the first implantation of the DIAMOND device in China. According to a 2013 Journal of the American Medical Association publication, 11.6% of the Chinese population, or 114 million individuals, have diabetes. China is burdened by diabetes more than any other country in the world.
The implantation of the DIAMOND device took place at the Beijing Tiantan Hospital, and was led by Professor Bai Rixing. “We are very excited to offer the DIAMOND therapy to our patients. Randomized trials indicate patients implanted with the DIAMOND experience long term improvement in glycemic control as well as an improvement in other metabolic parameters including blood pressure, weight, waist circumference and blood lipid levels,” commented Professor Bai.
Earlier this year the Diabetes Technology & Therapeutics journal published positive results from the first study comparing the effects of DIAMOND therapy against insulin treatment in obese Chinese patients. The study, which was conducted by Dr. Simon Kin-Hung Wong at the Chinese University of Hong Kong, showed glycemic control with DIAMOND therapy was as effective as insulin. Body weight, body fat, waist circumference and mean systolic blood pressure all decreased in the DIAMOND therapy arm, as opposed to the increase that was observed in these parameters in the insulin treatment arm. The study concluded that DIAMOND therapy was a well-tolerated alternative to insulin.
“This is an important step for the care of millions of Chinese suffering from type 2 diabetes,” added Dr. Zelewski, CEO of MetaCure.
About type 2 diabetes
Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance. The most common form of diabetes, it represents 90% of all cases. Often referred to as a pandemic, it is estimated that over 400 million people worldwide are affected by diabetes, with management costs exceeding $800 billion annually.
About DIAMOND therapy
DIAMOND therapy is delivered via an implantable medical device which has the potential to be used as an alternative to insulin. The safety and efficacy of DIAMOND therapy have been validated in clinical trials involving over 300 patients, including a pilot study which demonstrated a comparable effectiveness to insulin treatment, but avoiding many side-effects and the inconvenience of frequent blood tests and injections. Designed to treat type 2 diabetes in obese patients who are refractory to oral medication, DIAMOND therapy is delivered via a small pacemaker-like device implanted in the abdomen, which delivers electrical signals to the stomach when eating, improving glycemic control and promoting weight loss. DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets; it is currently not approved for use in the USA. For more information, visit www.MetaCure.com/DIAMOND.
MetaCure, a member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. It develops, produces and markets the DIAMOND therapy, an alternative to insulin delivered via a proprietary implantable device. For more information, visit MetaCure.com.
About Hobart Group
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit www.Hobart-Group.com.